June 22, 2017 09:17 AM EDT

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD

John Carroll

Editor & Founder

Santhera Pharmaceuticals saw its shares {SIX: $SANN} jump 16% today after the Swiss biotech reported that UK regulators will provide early access to their drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD

John Carroll

Editor & Founder

Sign up to read this article for free.

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Flagship biotech Valo Health ends 2024 with mid-stage fail

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

WuXi AppTec will sell cell and gene therapy business to private equity firm

UK reg­u­la­tors green-light ear­ly ac­cess to San­thera’s Rax­one for Duchenne MD

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Flagship biotech Valo Health ends 2024 with mid-stage fail

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

WuXi AppTec will sell cell and gene therapy business to private equity firm